Duration of Chemotherapy with Topotecan Influences Survival in Recurrent Ovarian Cancer: A Meta-analysis

• Published in: Anticancer research Vol. 27; no. 3B; pp. 1581 - 1588
• Main Authors: MOBUS, Volker, KIEBACK, Dirk G, KAUBITZSCH, Sabine K
• Format: Journal Article
• Language: English
• Published: Attiki International Institute of Anticancer Research 01.05.2007
• Subjects: Adult; Aged; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Biological and medical sciences; Clinical Trials as Topic; Female; Female genital diseases; Gynecology. Andrology. Obstetrics; Humans; Medical sciences; Middle Aged; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - mortality; Ovarian Neoplasms - drug therapy; Retrospective Studies; Survival; Topotecan - administration & dosage; Topotecan - adverse effects; Treatment Outcome; Tumors; Antineoplastic agent; Relapse; Enzyme; ovarian cancer; Ovary cancer; DNA topoisomerase; Enzyme inhibitor; meta-analysis; Topotecan; Malignant tumor; Long term; Survival; Female genital diseases; Metaanalysis; Ovarian diseases; Chemotherapy; Isomerases; Cancerology; Treatment; maintenance; long-term

Objective: This meta-analysis compares the feasibility, safety and clinical outcome of long-term therapy with topotecan vs. standard treatment duration in patients with recurrent ovarian cancer. Materials and Methods: Data of 523 patients from five clinical trials were reviewed and retrospectively a...